BBIO - Drug launch prices rise significantly outpacing inflation and GDP growth: ICER
2025-10-23 12:19:26 ET
More on Bristol-Myers Squibb, Johnson & Johnson, etc.
- The Play On Bristol-Myers Squibb
- Merck: Earnings Outlook Steady, Keytruda Now Has Some Breathing Room
- Merck: A Golden Buying Opportunity
- Merck Keytruda formulations undergo FDA priority review for bladder cancer
- Goldman Sachs rebalances dividend yields & growth equity basket as earnings season begins